SCHEMBL1469486

SCHEMBL1469486

O=[N+]([O-])c1cc2c(Cl)ncnc2cc1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.54
PGK1 P00558 1/20 0.44
LMNA P02545 2/20 0.42
PDGFRB P09619 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
VCAM1 P19320 3/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MAPT P10636 2/20 0.39
ENPP1 P22413 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30275314 1.00 EGFR (0.54) EGFRPGK1LMNAPDGFRBTSHR
SCHEMBL2997470 0.95 EGFR (0.50) EGFRPGK1LMNAPDGFRBTSHR
SCHEMBL16082531 0.85 EGFR (0.51) EGFRPGK1LMNAPDGFRBTSHR
SCHEMBL13083345 0.85 EGFR (0.51) EGFRPGK1LMNAPDGFRBTSHR
SCHEMBL25409 0.83 EGFR (0.41) EGFRLMNAALDH1A1VCAM1PDE4A
SCHEMBL14579636 0.83 GAA (0.43) EGFRTSHRALDH1A1CYP3A4PDE4A
SCHEMBL12488021 0.83 EGFR (0.46) EGFRALDH1A1PDE4APDE4BPDE4C
SCHEMBL29719180 0.83 EGFR (0.41) EGFRPDE4APDE4BPDE4CPDE4D
SCHEMBL22983685 0.83 EGFR (0.41) EGFRPDE4APDE4BPDE4CPDE4D
SCHEMBL29719028 0.83 EGFR (0.41) EGFRLMNAALDH1A1VCAM1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113354591-B Synthesis of alkylamino quinazoline and its antineoplastic activity 广东湛江海洋医药研究院 2023-03-24 CN disclosed
CN-113354591-A Synthesis of alkylamino quinazoline and its antineoplastic activity 广东湛江海洋医药研究院 2021-09-07 CN disclosed
CN-107674059-B Benzaheteroaromatic ring compound and preparation method and application thereof 中国药科大学 2020-04-14 CN disclosed
EP-3103799-A1 QUINAZOLINE DERIVATIVES OSI Pharmaceuticals, LLC (US) 2016-12-14 EP disclosed
EP-2163546-B1 Quinazoline derivatives PFIZER PROD INC (US) 2016-06-01 EP disclosed
WO-2014145512-A2 POTENT SMALL MOLECULE INHIBITORS OF AUTOPHAGY, AND METHODS OF USE THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2014-09-18 WO disclosed
EP-2248806-B1 Quinazoline derivatives as tyrosine kinase inhibitors SHANGHAI ALLIST PHARMACEUTICALS INC (CN) 2013-04-24 EP disclosed
CN-102942561-A 4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound SHENZHEN NEPTUNUS PHARMACEUTIC 2013-02-27 CN disclosed
US-8309563-B2 Quinazoline derivatives useful as anti-tumor medicament SHANGHAI ALLIST PHARMACEUTICALS, INC. (CN) 2012-11-13 US disclosed
US-8188274-B2 Process for preparing aminocrotonylamino-substituted quinazoline derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-29 US disclosed
EP-0817775-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1998-01-14 EP disclosed
EP-0794953-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1997-09-17 EP disclosed
EP-0790986-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1997-08-27 EP disclosed
WO-1996033981-A1 QUINAZOLINE DERIVATIVE ZENECA LIMITED (GB) 1996-10-31 WO disclosed
WO-1996030347-A1 QUINAZOLINE DERIVATIVES PFIZER INC. (US) 1996-10-03 WO disclosed
WO-1996016960-A1 QUINAZOLINE DERIVATIVES ZENECA LIMITED (GB) 1996-06-06 WO disclosed
WO-1996015118-A1 ANILINE DERIVATIVES ZENECA LIMITED (GB) 1996-05-23 WO disclosed
US-5475001-A Quinazoline derivatives ZENECA LIMITED (GB) 1995-12-12 US disclosed
WO-1995003283-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS ANTI-CANCER AGENTS ZENECA LIMITED (GB) 1995-02-02 WO disclosed
EP-0635498-A1 Quinazoline derivatives and their use as anti-cancer agents ZENECA LIMITED (GB) 1995-01-25 EP disclosed